Cantor Fitzgerald Weighs in on Kura Oncology FY2025 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Investment analysts at Cantor Fitzgerald raised their FY2025 EPS estimates for shares of Kura Oncology in a research report issued to clients and investors on Wednesday, March 19th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will earn ($2.21) per share for the year, up from their prior forecast of ($2.94). Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analysts’ expectations of $57.96 million.

KURA has been the topic of several other reports. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Kura Oncology in a research report on Thursday, February 27th. Wedbush reiterated an “outperform” rating and issued a $36.00 price objective on shares of Kura Oncology in a research report on Thursday, February 27th. StockNews.com lowered shares of Kura Oncology from a “buy” rating to a “hold” rating in a report on Tuesday, March 18th. JMP Securities restated a “market outperform” rating and issued a $28.00 target price on shares of Kura Oncology in a report on Thursday, February 6th. Finally, BTIG Research lowered shares of Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th. Four equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.50.

Kura Oncology Price Performance

Kura Oncology stock opened at $7.84 on Friday. Kura Oncology has a 52 week low of $6.79 and a 52 week high of $23.48. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm’s 50-day simple moving average is $7.82 and its 200 day simple moving average is $12.43. The firm has a market capitalization of $633.12 million, a PE ratio of -3.32 and a beta of 0.85.

Institutional Trading of Kura Oncology

Institutional investors and hedge funds have recently bought and sold shares of the business. Virtus ETF Advisers LLC increased its position in Kura Oncology by 71.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after purchasing an additional 3,061 shares in the last quarter. Harbor Advisors LLC acquired a new stake in Kura Oncology during the 4th quarter worth approximately $87,000. E Fund Management Co. Ltd. acquired a new stake in Kura Oncology during the 4th quarter worth approximately $90,000. Corton Capital Inc. acquired a new stake in Kura Oncology during the 4th quarter worth approximately $99,000. Finally, Optimize Financial Inc acquired a new stake in Kura Oncology during the 4th quarter worth approximately $100,000.

Insider Transactions at Kura Oncology

In other news, insider Mollie Leoni sold 4,963 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. This represents a 5.32 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,729 shares of company stock worth $92,307 in the last three months. Company insiders own 5.50% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.